Sector: Healthcare | Industry: Pharmaceuticals |
See Regulatory Filings on SEC |
Company Contact | |
Address: | UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN KY1-1104 |
Tel: | N/A |
Website: | https://www.theravance.com |
IR: | See website |
Key People | ||
Rick E. Winningham Chairman of the Board, Chief Executive Officer | Aziz Sawaf Chief Financial Officer, Senior Vice President | Brett A. Grimaud Senior Vice President, General Counsel, Secretary | Rhonda F. Farnum Senior Vice President - Commercial and Medical Affairs, Chief Business Officer |
Business Overview |
Theravance Biopharma, Inc. is a biopharmaceutical company primarily focused on the development, and commercialization of medicines. Its product, YUPELRI (revefenacin) inhalation solution is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). YUPELRI is a prescription medicine used to treat COPD, a long-term lung disease that includes chronic bronchitis, emphysema, or both. YUPELRI is an anticholinergic medicine, which helps the muscles around the airway in lungs stay relaxed to prevent symptoms, such as wheezing, shortness of breath and others. Its pipeline of internally discovered programs is targeted to address unmet patient needs. Ampreloxetine, its late-stage investigational norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension. Its Selective 5-HT4 Agonist (TD-8954) is a selective 5-HT4 receptor agonist, which is developed for the treatment of gastrointestinal motility disorders. |
Financial Overview |
For the fiscal year ended 31 December 2023, Theravance Biopharma Inc revenues increased 12% to $57.4M. Net loss before extraordinary items decreased 41% to $55.2M. Revenues reflect Europe segment increase of less than 1% to $223K. Lower net loss reflects Research and development - bal decrease of 36% to $32.6M (expense), Restructuring and related expenses decrease of 79% to $2.7M (expense). |
Employees: | 99 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $331.54M as of Dec 31, 2023 |
Annual revenue (TTM): | $57.42M as of Dec 31, 2023 |
EBITDA (TTM): | -$51.29M as of Dec 31, 2023 |
Net annual income (TTM): | -$55.19M as of Dec 31, 2023 |
Free cash flow (TTM): | -$29.49M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 48,164,708 as of Feb 23, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |